ALK wild-type
|
NSCLC
|
ALK wild-type
|
NSCLC
|
durvalumab Sensitive: B - Late Trials
|
durvalumab Sensitive: B - Late Trials
|
ALK wild-type
|
Lung Non-Squamous Non-Small Cell Cancer
|
ALK wild-type
|
Lung Non-Squamous Non-Small Cell Cancer
|
tislelizumab Sensitive: C3 – Early Trials
|
tislelizumab Sensitive: C3 – Early Trials
|
ALK wild-type
|
Lung Cancer
|
ALK wild-type
|
Lung Cancer
|
crizotinib Sensitive: D – Preclinical
|
crizotinib Sensitive: D – Preclinical
|